Prescribing guide
Tryngolza (olezarsen)80mg monthly dosing for FCS, liver enzyme testing, missed doses, autoinjector storage, network pharmacies and prior authorization criteriaFor prescribers and their offices treating familial chylomicronemia syndrome (FCS): what the pharmacy needs before it ships, what the prior authorization wants documented, the titration and the monitoring the label requires.
Dispensing gate
No REMS; e-prescription or faxed Start Form to a network pharmacy (Accredo, BlinkRx, CVS Specialty or Optum Specialty Pharmacy), prior authorization, the pharmacy's contact with the patient, and injection training before the first dose.
Example PA threshold
Cigna example: age 18 or older; documented baseline fasting TG of 880mg/dL or higher; biallelic pathogenic variants, or an inconclusive test with Moulin 10 or more or NAFCS 45 or more, or a clinical diagnosis; low-fat diet; cardiologist, endocrinologist, lipidologist or sHTG-focused physician.
Monitoring
No scheduled lab monitoring in the label; consider liver enzymes before initiation or a dose increase and when clinically indicated; watch for hypersensitivity; platelet reductions and glucose, HbA1c and LDL-C increases were seen in trials.
Support line
Ionis Every Step, 1-844-789-8744, Monday to Friday 8 AM to 8 PM ET (patients select option 2); patient consent page fax 1-877-299-0015; commercial copay as little as $0 per fill; Quick Start free drug during the insurance approval process; Bridge and Patient Assistance Program.
Give your patient their plan
A one-page handout for starting Tryngolza, in plain language: what the first fill waits on, the first dates, who will call and the symptoms to report, with blank lines for the start date and your office's number. The link opens the patient's full first 90 days page, where their dates become calendar entries.
trialfriend.com/p/tryngolzaBefore the first fill: REMS, labs and enrollment
The steps that the pharmacy, the REMS or the drugmaker's program will wait on, in the order they usually need to happen. A first fill of a specialty drug most often stalls on one of these rather than on the plan.
| Step | What it requires | Source |
|---|---|---|
| No REMS | Tryngolza does not appear in the FDA REMS data file, and the label sets no REMS and no boxed warning. | FDA REMS list |
| Prescribing route | e-Prescribe through the EHR to an in-network pharmacy, or fax the completed TRYNGOLZA Start Form to an in-network pharmacy. Some plans or PBMs require a specific pharmacy, so Ionis says to confirm with the patient's plan before sending. | HCP access page |
| Pharmacy network | Accredo (phone 1-844-516-3319, fax 1-888-302-1028), BlinkRx (1-844-926-2480, fax 1-866-585-4631), CVS Specialty (1-800-237-2767, fax 1-800-323-2445) and Optum Specialty Pharmacy (1-855-427-4682, fax 1-877-342-4596). BlinkRx is the digital pharmacy and can triage to a plan-mandated network pharmacy. CuraScript SD is the specialty distributor. | HCP access page |
| Prescription fields | For FCS: 80mg/0.8mL single-dose autoinjector, NDC 71860-101-01, 80mg subcutaneously once monthly, quantity 1, refills 11 months or other. Prescriber signature, no stamps, or an e-prescription to the selected pharmacy. New York providers also submit an electronic prescription. | Start Form |
| Clinical information | ICD-10-CM options on the form: E78.1, E78.2, E78.3 (hyperchylomicronemia), E78.4 (other hyperlipidemia, as printed on the form) or other. In the current ICD-10-CM code set E78.4 is a category, and the listed codes are E78.41 and E78.49 (other hyperlipidemia). The form asks for copies of triglyceride tests, acute pancreatitis history, past and current medications, and drug allergies. | Start Form |
| Quick Start | If eligible, the patient is enrolled once all prior authorization information is received. Free drug during the insurance approval process, available to all insured patients. Not for patients without insurance or after a final coverage determination; not billable to any insurer or government program. | Start Form |
| Patient consent | Page 3 of the Start Form is the patient authorization. Fax it to Ionis Every Step at 1-877-299-0015, not to the pharmacy. Patients can instead complete the authorization at TRYNGOLZA.com/Enroll. | Start Form |
| Coverage documentation | Ionis recommends recent fasting triglyceride results, the history of acute pancreatitis events and prior or current triglyceride therapies. It also lists the prescribing information, the FDA approval letter and a Letter of Medical Necessity, with a sample letter on its Resources page. | HCP access page |
| Prior authorization and appeals | All network pharmacies initiate prior authorization requests through CoverMyMeds or fax and provide support with appeals. They also connect eligible patients with coverage and affordability programs. | HCP access page |
| Shipment | The pharmacy contacts the patient to coordinate delivery, ships by free home delivery and provides injection training for the first dose. Ionis asks offices to encourage patients to save the pharmacy's number. | HCP access page |
| Injection training | Before initiation, train patients and/or caregivers on proper preparation and administration, per section 2.2 and the Instructions for Use. | FDA label |
| Diet counseling | Advise patients to maintain a low-fat diet in conjunction with Tryngolza, and instruct patients with FCS to consume 20g or less of fat per day. | FDA label |
Prior authorization criteria and what to document
One public policy as the example: Cigna, September 1, 2026. Approval the first approval lasts 6 months, and renewal is a year at a time after a response, such as lower triglycerides or fewer pancreatitis episodes. This version was reviewed on July 23, 2026, after the June 2026 label, and took effect September 1, 2026. It added severe hypertriglyceridemia as a second route with its own criteria and shortened the first FCS approval from 1 year to 6 months. Its reference list still cites the January 2025 prescribing information. Other plans set their own criteria, so this one is here as an example, not as a rule.
| Element | What the policy asks | In the chart | Source |
|---|---|---|---|
| Age | 18 years of age or older | Date of birth on the request | Cigna policy |
| Baseline triglycerides | Fasting triglyceride level of 880mg/dL or higher at baseline, meaning before treatment with a triglyceride-lowering medication | Dated fasting lipid panel [documentation required] | Cigna policy |
| Genetic confirmation | Biallelic pathogenic variants in at least one gene causing FCS, such as LPL, GPIHBP1, APOA5, APOC2 or LMF1 | Molecular genetic test report [documentation required] | Cigna policy |
| Inconclusive genetic test | Inconclusive molecular genetic results plus a Moulin FCS score of 10 or more, or a North American FCS score of 45 or more | Test report and the completed score [documentation required] | Cigna policy |
| Clinical diagnosis | All 3: acute pancreatitis not caused by alcohol or cholelithiasis, or recurrent hospitalizations for severe abdominal pain without other explainable cause; absence of secondary hypertriglyceridemia such as obesity or uncontrolled diabetes; lack of response to traditional triglyceride-lowering medications | Pancreatitis or admission records, problem list and medication history with responses | Cigna policy |
| Diet | Used concomitantly with a low-fat diet | Diet plan or dietitian note | Cigna policy |
| Prescriber | Prescribed by a cardiologist, an endocrinologist, a lipidologist or a physician who focuses in the treatment of disorders related to severe hypertriglyceridemia | Specialty on the request | Cigna policy |
| Initial duration | Approve for 6 months, changed from 1 year in the version effective September 1, 2026 | Start date, for the renewal calendar | Cigna policy |
| Continuation | Patient currently receiving Tryngolza who has experienced a response, such as lower triglycerides or fewer pancreatitis episodes; approve for 1 year | Follow-up triglycerides against baseline and the pancreatitis history | Cigna policy |
| Other route in the same policy | Hypertriglyceridemia: at least 1 triglyceride-lowering medication, fasting triglycerides of 500mg/dL or higher despite it, and a low-fat diet. This is the severe hypertriglyceridemia indication, not the FCS route | Not applicable to an FCS request | Cigna policy |
| Not covered | Any other use is considered not medically necessary, and receipt of sample product does not satisfy any criteria requirement | Indication on the request | Cigna policy |
Tryngolza dosing and titration
| When | Label | Source |
|---|---|---|
| FCS | 80mg subcutaneously once monthly in adults. | FDA label |
| sHTG, a separate indication | 50mg subcutaneously once monthly; may be increased to 80mg once monthly if tolerated and additional TG reduction is clinically indicated. The label states 50mg is not an approved dosing regimen for FCS. | FDA label |
| Missed dose | Administer as soon as possible, then resume at monthly intervals from the date of the most recently administered dose. | FDA label |
| Presentation | 80mg/0.8mL single-dose autoinjector, 1 per carton, NDC 71860-101-01; 50mg/0.8mL single-dose autoinjector, 1 per carton, NDC 71860-102-01. Clear, colorless to yellow solution. | FDA label |
| Administration | Abdomen or front of the thigh; the back of the upper arm only when a healthcare provider or caregiver injects. Remove from the refrigerator 30 minutes before injecting; no other warming methods. Do not use if cloudy, discolored or containing particulate matter. | FDA label |
| Storage | 2°C to 8°C (36°F to 46°F) in the original carton. May be stored at room temperature between 15°C and 30°C (59°F and 86°F) in the original carton for up to 6 weeks; discard if not used within that time. Do not expose to heat; protect from light. | FDA label |
| Trial 1 efficacy (FCS) | 66 adults with genetically identified FCS and fasting TG of 880mg/dL or higher; 80mg (n=22) against placebo (n=23). Fasting TG change at month 6 was -30% against +12%, a difference of -43% (95% CI -74 to -11; p=0.0084). Acute pancreatitis over 12 months: 1 patient (5%) against 7 (30%), described as numerical. | FDA label |
| Pharmacokinetics and pharmacodynamics | Tmax about 2 hours; terminal half-life about 4 weeks. Placebo-corrected fasting apoC-III change in FCS at 80mg: -57% at 1 month, -69% at 3 months, -72% at 6 months and -80% at 12 months. | FDA label |
| Specific populations | Pediatric safety and effectiveness not established. No dose adjustment at 65 years and older, in mild to moderate renal impairment (eGFR 30 to under 90mL/min) or in mild or moderate hepatic impairment. Not studied in severe renal impairment, end-stage renal disease or severe hepatic impairment. | FDA label |
Monitoring the Tryngolza label requires
| When | What | What the label says to do with it | Source |
|---|---|---|---|
| Any time | Hypersensitivity reactions | Bronchospasm, diffuse erythema, facial swelling, urticaria, chills and myalgias have been reported; instruct patients to seek medical attention promptly and discontinue. Contraindicated after serious hypersensitivity | FDA label |
| Before initiation or a dose increase, then as clinically indicated | Liver enzymes | Consider testing. For persistent elevations, such as 3x ULN or greater, consider dose interruption and/or dose reduction. Discontinue promptly for serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice | FDA label |
| sHTG trials | Liver enzyme increases of 3x ULN or greater | 7% on 80mg, 3% on 50mg and 3% on placebo. Mean values rose within the first 6 months, stayed within the normal range, stabilized, and returned toward baseline after discontinuation | FDA label |
| sHTG substudy | Hepatic fat fraction | Mean increase at 12 months of 4 percentage points on 80mg and 2 on 50mg, against 0 on placebo; the label calls the clinical meaningfulness uncertain | FDA label |
| Trials 1 to 3 | Platelet count | Mean decreases through week 53 of 6% (50mg, sHTG trials) to 10% (80mg, all trials); decreased platelet count in 12% against 4% on placebo in FCS; no major bleeding events associated with low platelet counts; no monitoring schedule specified | FDA label |
| Trial 1 (FCS) | Glucose and HbA1c | Mean increases in fasting glucose of up to 17mg/dL and in HbA1c of under 0.2 percentage points; hyperglycemia in 52% against 35% on placebo among patients without a history of diabetes; no monitoring schedule specified | FDA label |
| Trial 1 (FCS) | LDL-C and apoB | LDL-C rose 64% from a mean baseline of 23mg/dL, against 9% on placebo, and stayed under 70mg/dL in 74% of treated patients; non-HDL-C fell 18%; total apoB rose 20% against 9% | FDA label |
| When clinically appropriate | Triglycerides | Section 2.1 places this under the sHTG dose: assess TG when clinically appropriate, and the TG-lowering effect may be measured within 3 months after initiation. The FCS trial's primary endpoint was at month 6 | FDA label |
| Any time | Injection site reactions | 19% against 9% on placebo in FCS; in the sHTG trials they were the most common adverse reaction leading to discontinuation | FDA label |
| Postmarketing requirement | Drug-induced liver injury | The December 2024 approval letter requires completion of CORE, CORE 2 and a 2-year open-label extension to evaluate the potential for drug-induced liver injury, with a final report due June 2029. It also requests 15-day reports of liver toxicity cases through the 5th year after approval | FDA letter |
| Renewal | Triglycerides and pancreatitis episodes | Cigna approves 6 months initially, then 1 year at a time when the patient has experienced a response to therapy | Cigna policy |
Tryngolza drug interactions and contraindications
| Label category | Agents and what the label says | Source |
|---|---|---|
| Other drugs | The label has no drug interactions section; the interaction data it reports are in vitro, in section 12.3. | FDA label |
| CYP enzymes | In vitro, olezarsen is not an inhibitor or inducer of CYP450 enzymes. | FDA label |
| Transporters | Not a substrate or inhibitor of OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, MATE1, MATE2-K, BCRP, P-gp or BSEP in vitro. | FDA label |
| Protein binding | More than 99% bound to plasma proteins in vitro; does not displace warfarin or ibuprofen from plasma protein binding sites. | FDA label |
| Background lipid therapy | At entry to the FCS trial, patients in the 80mg and placebo groups were on statins (27%), omega-3 fatty acids (42%), fibrates (49%) or other lipid-lowering therapies (13%). | FDA label |
| QT interval | At 1.5 times the maximum approved recommended dosage, no QT prolongation to any clinically relevant extent. | FDA label |
| Pregnancy and lactation | No human pregnancy data; no adverse developmental effects with the unconjugated ASO in mice and rabbits at about 21 and 20 times the MRHD. Severe gestational hypertriglyceridemia may raise the risk of acute pancreatitis in pregnancy. No human or animal milk data for olezarsen; the unconjugated ASO was present in mouse milk at low levels. | FDA label |
Why a first fill stalls, and the fix
- Prior authorization pending or deniedCigna asks for a fasting triglyceride level of 880mg/dL or higher at baseline, with documentation. Baseline means the level before any triglyceride-lowering medicine was started. It also wants a patient aged 18 or older and a low-fat diet alongside Tryngolza. Cigna says documentation may include chart notes and laboratory tests.
- The plan wants proof of the FCS diagnosisCigna accepts a gene test showing disease-causing variants in both copies of an FCS gene. It also accepts an inconclusive gene test with a Moulin score of 10 or more or a North American FCS score of 45 or more. Its third route is a clinical diagnosis that meets every item on its list.
- No gene test on fileCigna's clinical route asks for pancreatitis not caused by alcohol or gallstones, or repeated hospital stays for severe unexplained belly pain. It also asks that other causes of high triglycerides are absent and that standard triglyceride medicines did not work. Other plans set their own rules for how the diagnosis is shown.
- The prescriber is not a specialist the plan listsCigna asks for a cardiologist, an endocrinologist, a lipidologist or a physician who focuses on disorders related to severe hypertriglyceridemia. The office names the prescriber's specialty on the prior authorization request.
- The first approval ran outCigna approves the first 6 months, then a year at a time once there is a response to therapy. It gives lower triglycerides or fewer pancreatitis episodes as examples of a response. The office sends the follow-up triglyceride results with the renewal request.
- The prescription went to a pharmacy outside the networkTryngolza is dispensed through Accredo, BlinkRx, CVS Specialty and Optum Specialty Pharmacy. Ionis says some plans require a specific one, so it is important to confirm with the plan before the prescription is sent. It says BlinkRx can pass a prescription to another network pharmacy that a plan requires.
- The medicine has not shippedIonis says the pharmacy calls or texts to review coverage and costs and to confirm delivery details. If you are not sure which pharmacy you are using, Ionis Every Step can tell you at 1-844-789-8744, option 2.
- An appeal after a denialIonis says the network pharmacies start prior authorization requests and provide support with appeals. Its prescriber site lists a sample Letter of Medical Necessity on its Resources page. Ionis also lists the prescribing information and the FDA approval letter as helpful materials to send.
- A copay you cannot payWith commercial insurance, Ionis says you may pay as little as $0 for each fill through the Ionis Every Step Copay Program. People who use Medicare, Medicaid, TRICARE, Department of Defense, Veterans Administration or other government programs for medicine costs are excluded.
- No insurance, or a plan that does not cover TryngolzaIonis says you may be eligible to get Tryngolza at no cost through the Ionis Every Step Patient Assistance Program. Staying eligible depends on reviews of insurance and financial information, including a yearly reapplication.
- A gap in insurance coverageIonis says its Bridge program may give a short-term supply at no cost during a temporary gap in commercial insurance. You have to be eligible, and program terms and limits apply.
Ionis Every Step
- A copay program where a person with commercial insurance may pay as little as $0 for each fill of Tryngolza
- No copay help for anyone who uses Medicare, Medicaid, TRICARE, Department of Defense, Veterans Administration or other government programs for medicine costs
- Other financial support programs for people without insurance or whose insurance does not cover Tryngolza
- Injection training, regular check-ins and extra support if you need more help using Tryngolza
- Digital resources on how to use Tryngolza, nutrition tips and tools, and treatment goals
- Quick Start, free Tryngolza during the insurance approval process for eligible insured patients, once the prior authorization information is in Start Form
- Bridge, a short-term supply at no cost during a temporary gap in commercial insurance, for people who are eligible Ionis Every Step brochure
- A Patient Assistance Program that may provide Tryngolza at no cost when insurance does not cover it or you have none, with a yearly reapplication Ionis Every Step brochure
- Home delivery from the network pharmacy, which also contacts you when a refill is due Getting started page
Questions prescribers' offices ask about Tryngolza
What is the Tryngolza dose for FCS?
The dose is 80mg subcutaneously once monthly in adults with FCS, per the June 2026 label (section 2.1). The 50mg once-monthly regimen, with the option to increase to 80mg, belongs to the severe hypertriglyceridemia indication, and the label states that 50mg is not an approved dosing regimen for FCS. Patients with FCS are instructed to consume 20g or less of fat per day.
Does Tryngolza have a REMS or required lab monitoring?
No REMS and no boxed warning appear in the June 2026 label, which carries 1 contraindication (prior serious hypersensitivity) and 2 warnings (sections 5.1 and 5.2). Section 5.2, added in June 2026, says to consider liver enzyme testing before initiation or an increase in dosage and when clinically indicated thereafter. Tryngolza is not in the FDA REMS data file.
What does the label say about a missed dose?
Administer as soon as possible after a missed dose, then resume at monthly intervals from the date of the most recently administered dose, per the June 2026 label (section 2.2).
How is the Tryngolza autoinjector stored?
At 2°C to 8°C (36°F to 46°F) in the original carton, or at room temperature between 15°C and 30°C (59°F and 86°F) in the original carton for up to 6 weeks, per the June 2026 label (section 16.2). Discard if not used within the 6 weeks at room temperature. Do not expose to heat, and protect from light.
What do insurers ask for to approve Tryngolza for FCS?
The Cigna policy shown here, effective September 1, 2026, asks for age 18 or older and a documented baseline fasting triglyceride level of 880mg/dL or higher. It accepts biallelic pathogenic variants, an inconclusive genetic test with a Moulin score of 10 or more or a NAFCS score of 45 or more, or a clinical diagnosis meeting 3 listed elements. It also requires a low-fat diet and a cardiologist, endocrinologist, lipidologist or physician focused on severe hypertriglyceridemia disorders. Initial approval is 6 months, then 1 year with a response.
Free email alert
Get an email when the Tryngolza label changes
One email the day the FDA revises the Tryngolza prescribing information, with a summary of what changed. No trial alerts or newsletter, and you can stop anytime.
Label changes for Tryngolza only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Sources
- DailyMed - TRYNGOLZA- olezarsen sodium injection, solution (prescribing information revised 6/2026, Patient Information and Instructions for Use revised 06/2026), Ionis Pharmaceuticals, Inc., via DailyMed and openFDA, 2026-07-03.
- Approved Risk Evaluation and Mitigation Strategies (REMS), FDA, 2026-11-13.
- Access and Support | TRYNGOLZA® (olezarsen) for FCS, Ionis Pharmaceuticals, 2026-11-13.
- Getting Started with TRYNGOLZA® | TRYNGOLZA® (olezarsen) for FCS, Ionis Pharmaceuticals, 2026-11-13.
- Ionis Every Step brochure: Let's Take This Step by Step, Together (US-OLZ-2400107 v3.0 06/2026), Ionis Pharmaceuticals, 2026-11-13.
- TRYNGOLZA Start Form (US-OLZ-2600487 v1.0 09/2026), Ionis Pharmaceuticals, 2026-11-13.
- Access and Support | TRYNGOLZA® (olezarsen), Ionis Pharmaceuticals, 2026-11-13.
- Hypertriglyceridemia - Tryngolza, Drug Coverage Policy IP0733, Cigna, 2026-09-01.
- NDA 218614/S-004 supplement approval letter, Tryngolza (olezarsen) injection, FDA, 2026-06-24.
- NDA 218614 approval letter, Tryngolza (olezarsen) injection, FDA, 2024-12-19.
A reference drawn from the July 3, 2026 label, the drugmaker's published program and one public insurer policy shown as an example, checked on November 13, 2026. Labels and policies change; the label on DailyMed and the plan's current policy govern. Trial Friend is not a medical provider. It reports what these documents say and does not judge whether a drug is safe or right for any patient; that is the prescriber's decision. Not a substitute for the prescribing information.